HIV treatment

Ask MedXY AI

Latest news

Tag

HIV/AIDSadherenceAfrica

Long-Acting Injectable HIV Therapy: Improving Viral Suppression in African Adults with Adherence Challenges

By MedXY|Oct 18, 2026

A Phase 3b trial in eastern and southern Africa showed that long-acting injectable cabotegravir plus rilpivirine is noninferior to oral dolutegravir-based therapy for maintaining viral suppression in HIV patients facing adherence challenges

Infectious DiseasescabotegravirHIV treatment

Long‑acting Cabotegravir–Rilpivirine Achieves Durable Viral Suppression at 96 Weeks in African CARES Trial: A Practical Leap for HIV Treatment Delivery

By MedXY|Nov 13, 2025

The CARES phase 3b trial in Africa found cabotegravir + rilpivirine long‑acting injections every 8 weeks noninferior to continued oral ART for viral suppression at 96 weeks, with an acceptable safety profile and implementation consideration